therapeutic vaccine + PD-1 knockout T cells

Therapeutic vaccine + PD-1 knockout T cells is a combination immunotherapy composed of a cancer-specific therapeutic vaccine and autologous T cells in which the PD-1 gene has been knocked out, typically via CRISPR-Cas9 gene editing. The therapeutic vaccine is designed to activate anti-tumor immunity, often by utilizing a recombinant fusion protein (such as PAP-GM-CSF, combining prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor) to stimulate patient-derived peripheral blood mononuclear cells (PBMCs). These activated immune cells are meant to enhance the recognition and killing of tumor cells expressing specific antigens.[3][5] The PD-1 knockout T cells are patient-derived T lymphocytes genetically modified to inactivate the PD-1 gene, thus preventing the immune-suppressive signaling that tumors exploit. Blocking PD-1 signaling allows these engineered T cells to sustain their cytotoxic function, resist exhaustion, and maintain cytokine production, leading to improved anti-tumor efficacy.[1][2][3][5][8] This combination approach aims to synergize the antigen-specific activation of the immune system by the vaccine with the checkpoint blockade provided by PD-1 disruption, allowing superior tumor infiltration and destruction by effector T cells. Primary indications under investigation include advanced solid tumors, with prostate cancer being a major focus.[3][5][7]

Other names

therapeutic vaccine-The First Affiliated Hospital of Guangdong Pharmaceutical University-prostate cancerTherapeutic vaccine and PD-1 knockout T cellsPAP-GM-CSF vaccine + CRISPR PD-1 knockout T cells